Drug Type Small molecule drug |
Synonyms SPR-519, SPR-965 |
Target |
Action inhibitors |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Preclinical | United States | 15 Feb 2021 | |
Neoplasms | Preclinical | India | - |